ADAPTOL ® [Mebicar]

Dosage and administration

The normal daily dose is 900 - 1800 mg: 300 - 600 mg thrice daily. The duration of a course of treatment can vary from several days to 2 months. If taken to relieve nicotine withdrawal symptoms, use 300 - 900 mg thrice daily for a period of 5 - 6 weeks.

Side effects

Side effects include allergic reactions (itchy skin), headaches, hypotension (low blood pressure), and low body temperature.

Overdose

An increase in potential side effects.

Note: Anecdotal reports in Russia show that Mebicar provides a good rapid effect in the majority of cases without causing sleepiness and grogginess. However, in 8 - 12 % of all cases, the drug appears either to be ineffective or to cause side effects.

Country of Manufacture: Russia

You can read the full instruction here (Adaptol)

You can read the full instruction here (Mebicar)

US Domestic shipping is available for this product! Choose Ships from: US size option to get it in 3-7 days to any US address. Dont forget to choose US Domestic Shipping when checking out.

Adaptol (also known as Mebicar) was synthesized at the Institute of Organic Chemistry by Ukranian professor V. M. Povstian. In 1978, the USSR Ministry of Healthcare approved Mebicar for use by the general public as an anxiolytic and as a “daily” tranquilizer. Mebicar belongs to a group of non-benzodizepam tranquilizers; from the chemical perspective, it is a derivative of carbamide, an endogenous metabolite, which explains why the compound is 150 times less toxic than Diazepam.

Mebicar works on the serotonergic system: taken in small doses it increases the effect of tryptophan, which is a precursor to serotonin.

Mebicar can be used by those who have the following symptoms:

  • Asthenic disorders
  • Depressions with anxiety
  • Various conditions characterised by reduced mental productivity
  • Extreme work conditions, e.g. excessive mental or physical exertion
  • Nicotine withdrawal
  • Impaired memory formation

Country of Manufacture: Russia / Latvia

Availability: in stock

  1. Zimakova et al (1980) Effect of mebikar on the state of animals under extreme conditions https://www.ncbi.nlm.nih.gov/pubmed/7439369
  2. Valdman et al (1980) Characteristics of the psychotropic spectrum of action of mebicar https://www.ncbi.nlm.nih.gov/pubmed/6104993
  3. S Kirshin, I Zimakova (1982) GABA-ergic component in the action of the tranquilizing agent mebikar https://www.ncbi.nlm.nih.gov/pubmed/7075749
  4. Zimakova et al (1986) Evaluation of the nootropic effect of mebikar in clinical practice https://www.ncbi.nlm.nih.gov/pubmed/3770177
  5. Zalesov et al (1988) Experimental and clinical study of the effectiveness of the combined use of anticonvulsants and tranquilizers in epilepsy https://www.ncbi.nlm.nih.gov/pubmed/3188750
  6. Chutko et al (2009) Adaptol in the treatment of ADHD https://www.ncbi.nlm.nih.gov/pubmed/19738569
  7. Mokina et al (2009) Experience of application of adaptol in treatment of chronic fatigue syndrome in patients with chronic cerebral ischemia https://www.ncbi.nlm.nih.gov/pubmed/19685596
  8. Chutko et al (2009) The use of adaptol in the treatment of tick hyperkinesis is children https://www.ncbi.nlm.nih.gov/pubmed/20209680
  9. Chutko et al (2010) Clinical and neurophysiological study of the efficacy of adaptol in the treatment of emotional burn-out https://www.ncbi.nlm.nih.gov/pubmed/21183911
  10. K Tursunova, L Chutko (2011) Adaptol in the treatment of chronic cervicogenic headache https://www.ncbi.nlm.nih.gov/pubmed/21905338
  11. E Barantsevich, O Posokhina (2011) Clinical-neurophysiological study of efficacy of adaptol in discirculatory encephalopathy https://www.ncbi.nlm.nih.gov/pubmed/22027612
  12. V Mkrtchian, L Kozhokova (2012) Adaptol-verges of possible https://www.ncbi.nlm.nih.gov/pubmed/23534281
  13. Shilina et al (2013) Efficacy of adaptol and the possibility of its differential use in patients with anxiety disorders after myocardial infarction https://www.ncbi.nlm.nih.gov/pubmed/24261227
  14. S Duma et al (2013) Efficiency of using the anxiolytic adaptol in the combination therapy of arterial hypertension in women https://www.ncbi.nlm.nih.gov/pubmed/23808300
  15. Orlov et al (2014) Clinical efficiency of combined therapy using adaptol for atopic dermatitis https://www.ncbi.nlm.nih.gov/pubmed/25026806
  16. Chutko et al (2014) Asthenic disorders in children and their differentiated treatment https://www.ncbi.nlm.nih.gov/pubmed/25726788
  17. Khaziakhmetova et al (2015) Experimental comparative study of the analgesic activity of the diurnal anxiolytic mebicar, amitriptyline, and diazepam https://www.ncbi.nlm.nih.gov/pubmed/26036004
  18. V Vorob'eva, V Repina (2016) An open comparative observational study of the efficacy and safety of adaptol in anxiety-asthenic disorders in patients with chronic cerebral ischemia https://www.ncbi.nlm.nih.gov/pubmed/27070467
  19. J Zhitkova, D Hasanova (2017) An experience of using mebicar in patients with autonomic dysfunction associated with anxiety disorder https://www.ncbi.nlm.nih.gov/pubmed/29265088
  20. Kim et al (2018) Preventive Effect of Mebicar and Ginsenoside Rg1 on Neurobehavioral and Immunological Disruptions Caused by Intermittent Unpredictable Stress in Mice https://www.ncbi.nlm.nih.gov/pubmed/29920498


Type: Nootropics




CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT